Radiolabeled imaging probes targeting angiogenesis for personalized medicine

Area of Science:

• Oncology
• Molecular Imaging
• Biomarker Development

Background:

• Angiogenesis is crucial for tumor growth, making anti-angiogenic therapy a key strategy in oncology.
• Mechanisms of anti-angiogenic drug action and resistance are not fully understood.
• Lack of biomarkers hinders patient selection for anti-angiogenic treatments.

Purpose of the Study:

• To review the development of radiolabeled probes for imaging key angiogenesis proteins.
• To explore the use of these probes in personalizing anti-angiogenic therapy.
• To elucidate drug mechanisms and resistance pathways non-invasively.

Main Methods:

• Development of radiolabeled probes targeting vascular endothelial growth factor (VEGF) and its receptor.
• Imaging integrin αvβ3, fibronectin, and matrix metalloproteases using nuclear imaging techniques.
• Quantification of target expression for patient stratification and treatment monitoring.

Main Results:

• Radiolabeled probes enable non-invasive imaging of angiogenesis markers.
• Imaging can reveal mechanisms of drug response and resistance.
• Personalized anti-angiogenic therapy can be facilitated through target expression quantification.

Conclusions:

• Non-invasive nuclear imaging offers a promising approach for personalized anti-angiogenic therapy.
• Radiolabeled probes can guide treatment decisions by assessing target engagement.
• Further development and validation of these probes are essential for clinical application.